Stonepine Capital Management LLC Purchases Shares of 7,500 Oruka Therapeutics, Inc. $ORKA

Stonepine Capital Management LLC purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 7,500 shares of the company’s stock, valued at approximately $713,775.

Other hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the fourth quarter worth $37,000. PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the third quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oruka Therapeutics during the 2nd quarter worth approximately $211,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

ORKA stock traded down $5.40 during midday trading on Friday, reaching $91.14. 589,422 shares of the company traded hands, compared to its average volume of 1,118,875. Oruka Therapeutics, Inc. has a 52-week low of $14.61 and a 52-week high of $115.51. The business has a 50 day moving average of $94.23 and a 200-day moving average of $67.34. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of -44.90 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at $64,503,670.20. This represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 83,116 shares of company stock valued at $6,636,533 in the last three months. Company insiders own 23.49% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ORKA shares. UBS Group lifted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Wedbush reiterated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.